Muris Anne-Hilde, Smolders Joost, Rolf Linda, Thewissen Marielle, Hupperts Raymond, Damoiseaux Jan
School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands; Academic MS Center Limburg, Zuyderland Medical Center, Sittard, The Netherlands.
Academic MS Center Limburg, Zuyderland Medical Center, Sittard, The Netherlands.
J Neuroimmunol. 2016 Nov 15;300:47-56. doi: 10.1016/j.jneuroim.2016.09.018. Epub 2016 Oct 3.
Multiple sclerosis (MS) is characterized by a disturbed immune homeostasis and low serum vitamin D levels are associated with an increased disease activity. While vitamin D has been hypothesized to promote the maintenance of immune homeostasis, vitamin D supplementation could be of benefit to patients with MS. The SOLAR study investigated the effects of high dose vitamin D supplementation on clinical outcomes in a randomized controlled trial. Here we present the immune regulatory effects, investigated in the SOLARIUM sub-study. Thirty Dutch relapsing remitting (RR) MS patients treated with IFNβ-1a received high dose vitamin D supplementation and 23 patients received placebo during a period of 48weeks. Lymphocytes were phenotypically characterized by flow cytometry and in vitro cytokine secretion was assessed in the presence or absence of 1,25(OH)D using Luminex technology. Changes in immune regulatory parameters were determined within subjects as well as between treatment groups. The proportion of cells in the immune regulatory cell compartment (nTreg, iTreg and Breg) was not altered upon high dose vitamin D supplementation. Proportions of T helper subsets were not affected by vitamin D, except for the proportion of IL4 Th cells, which decreased in the placebo but not in the vitamin D group. T cell cytokine secretion increased, most pronounced for IL5 and latency activated protein of TGFβ, in the placebo group but not in the vitamin D group. Lymphocytes remained equally reactive to in vitro 1,25(OH)D. In conclusion, high dose vitamin D supplementation did not result in a relative increase in lymphocytes with a regulatory phenotype. However, this study supports the hypothesis that vitamin D contributes to the maintenance of immune homeostasis by preventing further disturbance of the T cell compartment early in the disease course of MS.
多发性硬化症(MS)的特征是免疫稳态紊乱,血清维生素D水平低与疾病活动增加有关。虽然有假说认为维生素D有助于维持免疫稳态,但补充维生素D可能对MS患者有益。SOLAR研究在一项随机对照试验中调查了高剂量补充维生素D对临床结局的影响。在此,我们展示在SOLARIUM子研究中所调查的免疫调节作用。30名接受IFNβ-1a治疗的荷兰复发缓解型(RR)MS患者在48周期间接受高剂量维生素D补充,23名患者接受安慰剂。通过流式细胞术对淋巴细胞进行表型分析,并使用Luminex技术在存在或不存在1,25(OH)D的情况下评估体外细胞因子分泌。在个体内部以及治疗组之间确定免疫调节参数的变化。高剂量补充维生素D后,免疫调节细胞区室(nTreg、iTreg和Breg)中的细胞比例未改变。除IL4 Th细胞比例外,T辅助亚群的比例不受维生素D影响,IL4 Th细胞比例在安慰剂组中下降,但在维生素D组中未下降。安慰剂组中T细胞细胞因子分泌增加,以IL5和TGFβ的潜伏激活蛋白最为明显,而维生素D组未增加。淋巴细胞对体外1,25(OH)D的反应性保持不变。总之,高剂量补充维生素D并未导致具有调节表型的淋巴细胞相对增加。然而,本研究支持以下假说:在MS病程早期,维生素D通过防止T细胞区室的进一步紊乱有助于维持免疫稳态。